<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02060721</url>
  </required_header>
  <id_info>
    <org_study_id>AC-055E202</org_study_id>
    <nct_id>NCT02060721</nct_id>
  </id_info>
  <brief_title>Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension</brief_title>
  <acronym>MERIT-2</acronym>
  <official_title>Long Term, Multicenter, Single-arm, Open-label Extension Study of the MERIT-1 Study, to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used
      for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 9, 2015</start_date>
  <completion_date type="Anticipated">December 22, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 22, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-emergent adverse events (AEs) up to 30 days after study drug discontinuation</measure>
    <time_frame>From baseline up to 30 days after study drug discontinuation (up to 24 months from Visit 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AEs leading to premature discontinuation of study drug.</measure>
    <time_frame>From baseline up to 30 days after study drug discontinuation (up to 24 months from Visit 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-emergent serious adverse events up to 30 days after study drug discontinuation</measure>
    <time_frame>From baseline up to 30 days after study drug discontinuation (up to 24 months from Visit 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-emergent marked laboratory abnormalities up to 30 days after study drug discontinuation</measure>
    <time_frame>From baseline up to 30 days after study drug discontinuation (up to 24 months from Visit 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in vital signs (arterial blood pressure, heart rate) and body weight from baseline to all assessed time points during the study</measure>
    <time_frame>From baseline up to 24 months</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Change from baseline to each scheduled time point inexercise capacity, as measured by the 6MWD</measure>
    <time_frame>Baseline up to 30 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline to each scheduled time point in Borg dyspnea index</measure>
    <time_frame>Baseline up to 30 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects with worsening of WHO FC from baseline to each scheduled time point.</measure>
    <time_frame>Baseline up to 30 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>marked laboratory abnormalities during treatment period and up to 30 days after study drug discontinuation</measure>
    <time_frame>From baseline up to 30 days after study drug discontinuation.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in vital signs (blood pressure , heart rate) and body weight from baseline to all assessed time points during the study</measure>
    <time_frame>From baseline up to 30 days after study drug discontinuation.</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Chronic Thromboembolic Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Macitentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Macitentan 10mg, oral tablet, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Macitentan</intervention_name>
    <description>Macitentan 10mg, oral tablet, once daily</description>
    <arm_group_label>Macitentan</arm_group_label>
    <other_name>ACT-064992</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Subject with CTEPH having completed the double-blind (DB) AC-055E201/ MERIT-1 study as
             scheduled (i.e., who remained in the DB study up to Week 24).

          -  Females of childbearing potential must have a negative pre-treatment serum pregnancy
             test, be advised on appropriate methods of contraception, and agree to use 2 reliable
             methods of contraception.

        Exclusion Criteria:

          -  Permanent discontinuation of DB study treatment due to an hepatic adverse event or
             liver aminotransferase abnormalities.

          -  Any known factor (e.g., drug or substance abuse) or disease (e.g., unstable
             psychiatric illness) that, in the opinion of the investigator, may interfere with
             treatment compliance or interpretation of the results, or that may influence the
             ability to comply with any of the study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Gasthuisberg / Interne Geneeskunde - I.G. Pneumologie</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital-Department of Respiration</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular institute &amp; Fuwai Hospital- Thrombus Center</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 1St Affiliated Hosp of Guangzhou Med Univ-Resp Dept</name>
      <address>
        <city>Guangzhou</city>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital, Department of Pulmonary Circulation</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The General Hosp of Shenyang Military Region</name>
      <address>
        <city>Shenyang</city>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wu Han Asia Heart Hosp</name>
      <address>
        <city>Wuhan</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for PPH, Charles University , II Interni klinika1.LF a VFN</name>
      <address>
        <city>Praha</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre cedex</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou Service de Pneumologie, soins intensifs et endoscopies bronchiques</name>
      <address>
        <city>Paris cedex 15</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse Hopital Larrey</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig-Universität Gießen</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik am Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missionsärztliche Klinik gGmbH Akademisches Lehrkrankenhaus der Julius-Maximilians-Universität</name>
      <address>
        <city>Würzburg</city>
        <zip>97074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Orvos- és Egészségtudományi Centrum, Kardiológiai Klinika</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaunas Hospital of Lithuanian Univ of Health Pulmonology</name>
      <address>
        <city>Kaunas</city>
        <zip>50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cardiología (INC) Ignacio Chávez</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Lublin State</name>
      <address>
        <city>Lublin</city>
        <zip>20-718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny we Wrocawiu</name>
      <address>
        <city>Wrocaw</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sci Institute Systemic Problems Cardio Diseases Kemerovo</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Cardiology Scientific and Production Complex</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E.N.Meshalkin Novosibirsk State Research Institute Of Circulation Pathology Rosmedtechnology</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution &quot;Federal center of Heart, Blood and Endocrinology named after V.A.Almazov Rosmedtekhnologies&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;Research Institute for Cardiology&quot; of Siberian Branch under the Russian Academy of Medical Sciences / Cardiovascu</name>
      <address>
        <city>Tomsk</city>
        <zip>634012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital, Division of Respiratory and Respiratory Critical Care Medicine</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital, Division of Respiratory Disease and Tuberculosis</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAHARAJ NAKORN CHIANG MAI HOSPITAL, Department of Internal Medicine</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University İstanbul Faculty Medicine Pulmonology Department</name>
      <address>
        <city>Capa_Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Inst of Phthisiology and Pulm, Yanovskiy of Ams</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv Reg Clin Hosp, Cardiosurgery</name>
      <address>
        <city>Lviv</city>
        <zip>79014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital NHS Trust, Pulmonary Vascular Diseases Unit</name>
      <address>
        <city>Cambridge</city>
        <zip>CB23 3RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire - Pulm Vascular Med</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2RX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>China</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>South Africa</country>
    <country>Switzerland</country>
    <country>United States</country>
    <country>Vietnam</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2014</study_first_submitted>
  <study_first_submitted_qc>February 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2014</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic thromboembolic pulmonary hypertension (CTEPH)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macitentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

